Skip to content

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

Livio Erne, Severin B Vogt, Lorenz Müller, Albiona Nuraj, Anna M Becker, Aaron Klaiber, Melani Zuparic, Nimmy Varghese, Anne Eckert, Deborah Rudin, Dino Luethi, Matthias E. Liechti

Neuropsychopharmacology December 19, 2024 DOI: 10.1038/s41386-024-02041-8 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Double-blind, randomized, placebo-controlled, crossover design Peer reviewed
Sample size 22
Population Healthy participants (11 women, 11 men)
Intervention DMT
Dose 0.6, 1.2, 1.8, and 2.4 mg/min
Duration 120-minute infusion, with pharmacokinetics measured up to 3 hours after starting the infusion
Topics 5-MeO-DMT DMT
Keywords Psychedelic medicine DMT Research Controlled substance trials Psychopharmacology Dosage optimization
Citations 14
Key points Continuous DMT infusions produce dose-dependent subjective effects with a ceiling for good drug effect at 1.8 mg/min, while the 2.4 mg/min dose increases anxious ego dissolution and anxiety.

Abstract

Abstract N,N -dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a subsequent continuous infusion. However, data on dose-dependent acute effects and pharmacokinetics of continuous DMT infusions are lacking. We used a double-blind, randomized, placebo-controlled, crossover design in 22 healthy participants (11 women, 11 men) who received placebo and DMT (0.6, 1.2, 1.8, and 2.4 mg/min) over an infusion duration of 120 min. We also tested a self-guided titration scheme that allowed participants to adjust the DMT dose rate at prespecified time points to achieve their desired level of subjective effects. Outcome measures included subjective effects, autonomic effects, adverse effects, plasma hormone concentrations, and pharmacokinetics up to 3 h after starting the infusion. DMT infusions exhibited dose-proportional pharmacokinetics and rapidly induced dose-dependent subjective effects that reached a plateau after 30 min. A ceiling effect was observed for “good drug effect” at 1.8 mg/min. The 2.4 mg/min dose of DMT induced greater anxious ego dissolution than the 1.8 mg/min dose and induced significant anxiety compared with placebo. We observed moderate acute tolerance to acute effects of DMT. In the self-guided titration session, the participants opted for moderate to strong psychedelic effects, comparable in intensity to the 1.8 mg/min DMT dose rate in the randomized dosing sessions. These results may assist with dose finding for future DMT research and demonstrate that acute subjective effects of DMT can be rapidly adjusted through dose titration.